New approach to antifungal drugs that permanently disable fungal targets
Official title: Implementing a New Paradigm for Antifungal Drug Development
Funded at University of Toledo · NIH-11264984 · Data updated 2026-11-12
A new type of antifungal drug approach aims to permanently inactivate a fungal enzyme to kill or stop drug-resistant fungi.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project start | June 11, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $216,770 |
| NIH project number | 1R21AI195315-01 |
| Project ID | NIH-11264984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with suspected or confirmed invasive fungal infections caused by Aspergillus fumigatus or related fungi, particularly where resistance limits current therapies.
✕Less likely to help
Patients without fungal infections or with infections unlikely to respond to covalent inactivators may not benefit.
What this research studies
This project plans to design and test covalent inactivators that selectively bind and irreversibly disable a fungal enzyme essential for Aspergillus fumigatus survival. The researchers will optimize potency and target selectivity to turn promising compounds into potential drug candidates. The work focuses on proving the concept in early studies, with attention to how these agents behave in biological systems and their potential to overcome resistance. This is one step toward creating new treatments for serious fungal infections that are harder to treat today.
Why it matters
Potential benefit: If successful, patients with drug-resistant fungal infections could have new treatment options.
How similar studies have gone: Previous covalent drug approaches exist in other areas, but this project tests a novel antifungal strategy with early, exploratory aims.
Where this research is happening
-
University of Toledo
Toledo, United States Active
Researchers
- Principal investigator: Viola, Ronald Edward — University of Toledo
- Study coordinator: Viola, Ronald Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.